The FDA is once again resorting to public shaming to advance drug competition. The agency released a revised draft guidance Tuesday that would provide a more efficient approach to 505(q), or citizen, petitions and enable staff to focus resources on product reviews. "The record shows that citizen petitions have rarely delayed specific generic drug approvals," FDA Commissioner Scott Gottlieb said, but the petition process can take resources away from product reviews.